AlphAIAlphAI — Financial news for AI agents
tradingview.com$ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Reports Liver Fat Normalization Sustained Through Week 36

Regeneron reported that a single dose of CIDEBsiRNA normalized liver fat and improved injury markers in MASLD patients, with effects lasting through week 36. Alnylam is eligible for milestones and royalties. Regeneron holds exclusive commercialization rights.

Original reporting
tradingview.com
Published Nov 10, 2026, 3:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Alnylam Pharmaceuticals, Inc. (ALNY) Reports Liver Fat Normalization Sustained Through Week 36 — source image
Source · tradingview.com
Decision brief

The 30-second read

$ALNYBullishMed
01

Why it matters

The data creates a potential revenue stream for Alnylam via milestone and royalty agreements.

02

Market read

First report of promising trial data that could translate into future payments for Alnylam, offering a modest trade catalyst.

03

What to watch

Regeneron's exclusive commercialization rights could limit Alnylam's upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Regeneron disclosed first‑in‑human data for CIDEBsiRNA, showing liver‑fat normalization through week 36.

Company-level read

Ticker impact

$ALNYBullishMedium confidence
Context

Alnylam is eligible for development milestones and up to 20% tiered royalties from Regeneron's CIDEBsiRNA trial results.

Expected impact

potential upside as investors price in royalty upside

Evidence & confidence

The trial shows sustained liver‑fat reduction, creating a credible path for Alnylam payments.

Market effects

Sector

May lift sentiment for RNA‑based therapeutics and related biotech stocks.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Royalty payments are contingent on later trial phases; early hype may be premature.

Key entities

  • Company
    Regeneron Pharmaceuticals

    Conducted the trial and holds commercialization rights.

  • Company
    Alnylam Pharmaceuticals

    Potential royalty recipient from the CIDEBsiRNA program.

Read at source← All news

Related articles

$ALNYMedAI 9/10

Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM

Alnylam Pharmaceuticals (ALNY) reported five-year data from the HELIOS-B study, showing that early treatment with AMVUTTRA (vutrisiran) in ATTR-CM patients led to better long-term outcomes, including a 48% reduction in mortality and cardiovascular events in the monotherapy group. The study also showed improved quality of life and stability in cardiac biomarkers. The safety profile remained consistent. The findings were presented at the American Heart Association Scientific Sessions 2026.

rttnews.com
$ALNYMed

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

Alnylam Pharmaceuticals presented five-year data from the HELIOS-B study, showing sustained benefits of AMVUTTRA (vutrisiran) in treating ATTR-CM, including lower mortality and cardiovascular events, improved quality of life, and stable cardiac biomarkers. Early treatment initiation was highlighted as crucial. The study also demonstrated preserved exercise capacity and cardiac function with AMVUTTRA. The safety profile remained consistent.

finance.yahoo.com